CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.

about

Candesartan.Pharmacological management of cardiovascular conditions and diabetes in older adults with HIV infection.Functional characterization of 32 CYP2C9 allelic variants.

P2860

Q34375649-99DEB462-4521-40A0-826E-8E1CA785AB43 Q38172305-CA3418C3-FFEA-4647-8C08-D75F299324E1 Q50920357-CA602339-B27B-4AF7-9762-FA8F29AE8188

P2860

CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.

Item

http://www.wikidata.org/entity/Q43927415

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.

@en

CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.

@nl

type

Item

label

CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.

@en

CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.

@nl

prefLabel

CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.

@en

CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.

@nl

P1476

CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.

@en

P2093

J Azuma

http://www.w3.org/2001/XMLSchema#string

M Ikeda

http://www.w3.org/2001/XMLSchema#string

S Imaoka

http://www.w3.org/2001/XMLSchema#string

T Fukuda

http://www.w3.org/2001/XMLSchema#string

T Hanatani

http://www.w3.org/2001/XMLSchema#string

T Hiroi

http://www.w3.org/2001/XMLSchema#string

Y Funae

http://www.w3.org/2001/XMLSchema#string

P2860

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele

Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity

Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.

Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.

Expression of rat NADPH-cytochrome P-450 reductase cDNA in Saccharomyces cerevisiae.

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.

Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

P2888

sj.tpj.6500063

P304

288-292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.TPJ.6500063

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2001-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11455142

http://www.w3.org/2001/XMLSchema#string

P698

11908770

http://www.w3.org/2001/XMLSchema#string

CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.

about

P2860

P2860

CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698